<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="trial evaluating the efficacy, safety, and tolerability of fingolimod. Currently," exact="fingolimod" post="is the only Food and Drug Administration and European"/>
 <result pre="POMS. This review will critically evaluate the available evidence of" exact="fingolimod" post="in the treatment of POMS in detail, as well"/>
 <result pre="delay disability progression. Injectable therapies, which comprise of interferons and" exact="glatiramer acetate," post="have been approved by the European Medicines Agency (EMA)"/>
 <result pre="focus on discussing the safety, efficacy, and tolerability profile of" exact="fingolimod" post="in the POMS population. Fingolimod Experience In POMS Observational"/>
 <result pre="Observational Studies Prior to the randomized controlled PARADIGMS trial, 18" exact="fingolimod" post="experience in POMS population has been limited to small"/>
 <result pre="Huppke et al, involving highly active POMS patients on either" exact="natalizumab" post="or fingolimod published in 2017, analyzed relapse rate and"/>
 <result pre="al, involving highly active POMS patients on either natalizumab or" exact="fingolimod" post="published in 2017, analyzed relapse rate and MRI data"/>
 <result pre="There were a total of 23 POMS patients in the" exact="fingolimod" post="group with available data. Compared to the general POMS"/>
 <result pre="more aggressive disease at onset and were only switched from" exact="natalizumab" post="to fingolimod due to prolonged treatment duration and John"/>
 <result pre="disease at onset and were only switched from natalizumab to" exact="fingolimod" post="due to prolonged treatment duration and John Cunningham Virus"/>
 <result pre="adverse cardiac events or any serious side effects while on" exact="fingolimod" post="reported in this cohort. Of the side effects that"/>
 <result pre="2005, the combined group comprised of POMS patients on either" exact="natalizumab" post="or fingolimod in this more contemporary cohort experienced lower"/>
 <result pre="combined group comprised of POMS patients on either natalizumab or" exact="fingolimod" post="in this more contemporary cohort experienced lower relapse rate"/>
 <result pre="lower scores confer less disability). The other observational study of" exact="fingolimod" post="in POMS was published by Fragoso et al in"/>
 <result pre="Descriptive data from 17 POMS patients who were treated with" exact="fingolimod" post="before the age of 18 were reported. The POMS"/>
 <result pre="of 18 were reported. The POMS patients were treated with" exact="fingolimod" post="for an average of 8.6 months (range 1–18 months)."/>
 <result pre="registry, there were a total of 8 patients treated with" exact="fingolimod" post="(3 treated within 1 year of symptom onset and"/>
 <result pre="2 patients had abnormal blood counts with 1 patient discontinuing" exact="fingolimod" post="as well. Case Report Rebound of disease activity following"/>
 <result pre="fingolimod as well. Case Report Rebound of disease activity following" exact="fingolimod" post="discontinuation has been reported in AOMS. 22– 24 To"/>
 <result pre="she continued to have clinical and radiographic relapses, resulting in" exact="fingolimod" post="discontinuation for lack of efficacy. Fifty days following fingolimod"/>
 <result pre="in fingolimod discontinuation for lack of efficacy. Fifty days following" exact="fingolimod" post="discontinuation, she experienced a more severe relapse with significantly"/>
 <result pre="is only 1 published pivotal trial which evaluated efficacy of" exact="fingolimod" post="in POMS. The PARADIGMS study is a randomized, multicenter,"/>
 <result pre="multicenter, double-blind, double-dummy, active-controlled, parallel-group trial that compared efficacy of" exact="fingolimod" post="against interferon beta-1a in POMS. 18 Patients enrolled in"/>
 <result pre="double-dummy, active-controlled, parallel-group trial that compared efficacy of fingolimod against" exact="interferon beta-1a" post="in POMS. 18 Patients enrolled in PARADIGMS had confirmed"/>
 <result pre="prior to randomization. Patients were randomly assigned to receive either" exact="fingolimod" post="(oral 0.25 mg – 0.5 mg capsule once daily"/>
 <result pre="0.5 mg capsule once daily depending on body weight), or" exact="interferon beta-1a" post="(intramuscular injection 30 µg once weekly) for up to"/>
 <result pre="profile of both drugs in this trial. The effect of" exact="fingolimod" post="on time to 3-month sustained and confirmed disability worsening"/>
 <result pre="patients were enrolled, and 107 patients were randomly assigned to" exact="fingolimod" post="and 108 to interferon beta-1a. Trial completion rates were"/>
 <result pre="107 patients were randomly assigned to fingolimod and 108 to" exact="interferon beta-1a." post="Trial completion rates were 93.5% in fingolimod group and"/>
 <result pre="108 to interferon beta-1a. Trial completion rates were 93.5% in" exact="fingolimod" post="group and 81.5% in interferon beta-1a group. The demographic"/>
 <result pre="completion rates were 93.5% in fingolimod group and 81.5% in" exact="interferon beta-1a" post="group. The demographic spread of recruited patients in the"/>
 <result pre="group had significantly lower annualized relapse rate (0.12) compared to" exact="interferon beta-1a" post="(0.67). Similar favorable trends for fingolimod were found in"/>
 <result pre="(0.12) compared to interferon beta-1a (0.67). Similar favorable trends for" exact="fingolimod" post="were found in secondary end-points as well, including time"/>
 <result pre="well, including time to first relapse (fingolimod 720 days vs." exact="interferon beta-1a" post="488 days), percentage of patient free of relapse at"/>
 <result pre="free of relapse at 24 months (fingolimod group 85.7% vs." exact="interferon beta-1a" post="38.8%), annualized rate of new or enlarging T2-weighted MRI"/>
 <result pre="of new or enlarging T2-weighted MRI lesions (fingolimod 4.39 vs." exact="interferon beta-1a" post="9.27), gadolinium-enhancing lesions (fingolimod 0.44 vs. interferon beta-1a 1.28)."/>
 <result pre="4.39 vs. interferon beta-1a 9.27), gadolinium-enhancing lesions (fingolimod 0.44 vs." exact="interferon beta-1a" post="1.28). Exploratory analysis involving brain volume change, T2-weighted MRI"/>
 <result pre="analysis of time to confirmed 3-month disability worsening showed that" exact="fingolimod" post="significantly delayed its onset compared to interferon beta-1a. Overall"/>
 <result pre="worsening showed that fingolimod significantly delayed its onset compared to" exact="interferon beta-1a." post="Overall adverse events incidence for fingolimod (88.8%) was comparable"/>
 <result pre="onset compared to interferon beta-1a. Overall adverse events incidence for" exact="fingolimod" post="(88.8%) was comparable to that of interferon beta-1a (95.3%)."/>
 <result pre="events incidence for fingolimod (88.8%) was comparable to that of" exact="interferon beta-1a" post="(95.3%). Fingolimod group experienced more adverse events that led"/>
 <result pre="experienced more adverse events that led to discontinuation (5.6% vs" exact="interferon beta-1a" post="0.9%). There were more serious adverse events in the"/>
 <result pre="beta-1a 0.9%). There were more serious adverse events in the" exact="fingolimod" post="group (16.8%) compared to interferon beta-1a (6.5%). In the"/>
 <result pre="serious adverse events in the fingolimod group (16.8%) compared to" exact="interferon beta-1a" post="(6.5%). In the fingolimod group, there were 6 patients"/>
 <result pre="fingolimod group (16.8%) compared to interferon beta-1a (6.5%). In the" exact="fingolimod" post="group, there were 6 patients who had convulsions compared"/>
 <result pre="had convulsions compared to 1 patient with convulsions in the" exact="interferon beta-1a" post="group. Out of the 6 patients with convulsions in"/>
 <result pre="beta-1a group. Out of the 6 patients with convulsions in" exact="fingolimod" post="group, 2 were categorized as having serious adverse events."/>
 <result pre="macular edema reported, among others. Serious infections occurred in 4" exact="fingolimod" post="patients (3.7%) compared to 2 patients in the interferon"/>
 <result pre="4 fingolimod patients (3.7%) compared to 2 patients in the" exact="interferon beta-1a" post="group (1.9%), the infections included appendicitis, cellulitis, gastrointestinal infection,"/>
 <result pre="the PARADIGMS trial, 18 both FDA and EMA have approved" exact="fingolimod" post="use in POMS population. Results from the PARADIGMS trial"/>
 <result pre="Results from the PARADIGMS trial demonstrated that fingolimod, compared to" exact="interferon beta-1a," post="significantly reduced annualized relapse rate (82% reduction), annualized rate"/>
 <result pre="and mean number of gadolinium enhancing lesions (63% reduction). Furthermore," exact="fingolimod" post="also significantly delayed time to first relapse and 3-month"/>
 <result pre="in the limited number of previously published observational studies involving" exact="fingolimod" post="in POMS. 19– 21 Based on safety and tolerability"/>
 <result pre="tolerability data from both observational studies and the PARADIGMS trial," exact="fingolimod" post="appeared to be well-tolerated in POMS. Adverse events from"/>
 <result pre="fingolimod’s mechanism of action, increase infection risks. Discontinuation rate of" exact="fingolimod" post="was less than 6% in PARADIGMS. Despite only 1"/>
 <result pre="bradyarrythmia and herpes virus infection should be applied when prescribing" exact="fingolimod" post="for POMS as per protocol in AOMS. There was"/>
 <result pre="report of rebound disease activity in a POMS patient following" exact="fingolimod" post="discontinuation. 25 Therefore, strict adherence should be emphasized to"/>
 <result pre="prescribing fingolimod. There is a theoretical risk of PML with" exact="fingolimod" post="in POMS, as there have been 19 AOMS patients"/>
 <result pre="developing neurological and immunological systems. The long-term neurodevelopmental effects of" exact="fingolimod" post="in POMS is unknown, due to lack of longitudinal"/>
 <result pre="delaying disability worsening. 18 The unique lymphocytic sequestration mechanism of" exact="fingolimod" post="should also be taken into consideration when prescribing fingolimod"/>
 <result pre="of fingolimod should also be taken into consideration when prescribing" exact="fingolimod" post="in POMS patients with maturing adaptive immune systems. The"/>
 <result pre="repeated immune challenges. 13 Therefore, the potential long-term effects of" exact="fingolimod" post="on the development of comprehensive adaptive immune defense system"/>
 <result pre="Arnold DL , Banwell B , et al. Trial of" exact="fingolimod" post="versus interferon beta-1a in pediatric multiple sclerosis. N Engl"/>
 <result pre=", Banwell B , et al. Trial of fingolimod versus" exact="interferon beta-1a" post="in pediatric multiple sclerosis. N Engl J Med ."/>
 <result pre="MA , Baroncini D , et al. Disease reactivation after" exact="fingolimod" post="discontinuation in two multiple sclerosis patients. J Neurol ."/>
 <result pre="L , Pasto L , Amato MP . Withdrawal of" exact="fingolimod" post="treatment for relapsing-remitting multiple sclerosis: report of six cases"/>
 <result pre="Kumpfel T . Rebound of disease activity after withdrawal of" exact="fingolimod" post="(FTY720) treatment. Arch Neurol . 2012; 69( 2): 262–"/>
</results>
